# US 2025/0367289 A1 · Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367289 A1
- Document ID: US20250367289A1
- Status: Published application
- Kind: A1
- Application number: 18/874,958
- Filed: 2023-06-15
- Published: 2025-12-04
- Earliest claimed: 2022-06-16
- Assignees: Adaptimmune Limited
- Applicants: Adaptimmune Limited
- Inventors: Jose SARO; Steve DAWE; Alejandro GARCIA
- Web page: https://patentgrep.com/patent/US20250367289A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4268: {MAGE}
- A61K 40/4271: {Melanoma antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to a method of treating cancer, and to a population of modified T cells for use in a method of treating cancer.

## Claims

### Claim 1

A method of treating cancer in an individual, comprising:
(a) administering to the individual a population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4; and
(b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of a PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).

### Claim 2

A population of modified T cells for use in a method of treating cancer in an individual, wherein the modified T cells comprise a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4, and the method comprises:
(a) administering the population to the individual; and
(b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of a PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).

### Claim 3

A PD-1 axis binding antagonist for use in a method of treating cancer in an individual, wherein the method comprises:
(a) administering to the individual a population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4; and
(b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of the PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).

### Claim 4 (depends on 1, 2, 3)

The method of claim 1, population for use of claim 2, or PD-1 axis binding antagonist for use of claim 3, wherein the initial dose of the PD-1 axis binding antagonist is administered to the individual about four weeks after administration of the population of modified T cells.

### Claim 5 (depends on 1, 2, 3, 4)

The method of claim 1 or 4, population for use of claim 2 or 4, or PD-1 axis binding antagonist for use of claim 3 or 4, wherein the method further comprises administering one or more further doses of the PD-1 axis binding antagonist, optionally wherein the one or more further doses are administered once every four weeks (Q4W) beginning four weeks from administration of the initial dose.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1, 4 and 5, the population for use of any one of claims 2, 4 and 5, or the PD-1 axis binding antagonist for use of any one of claims 3 to 5, wherein administration of the PD-1 axis binding antagonist reduces exhaustion (i) within the population of modified T cells and/or within T cells descended from the population of modified T cells, and/or (ii) within endogenous T cells in the individual.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 and 4 to 6, the population for use of any one of claims 2 and 4 to 6, or the PD-1 axis binding antagonist for use of any one of claims 3 to 6, wherein the heterologous TCR binds to SEQ ID NO: 1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 and 4 to 7, the population for use of any one of claims 2 and 4 to 7, or the PD-1 axis binding antagonist for use of any one of claims 3 to 7, wherein the heterologous TCR comprises an alpha chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 and 4 to 8, the population for use of any one of claims 2 and 4 to 8, or the PD-1 axis binding antagonist for use of any one of claims 3 to 8, wherein the heterologous TCR comprises a beta chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 and 4 to 9, the population for use of any one of claims 2 and 4 to 9, or the PD-1 axis binding antagonist for use of any one of claims 3 to 9, wherein the CD8 co-receptor is CD8α.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 and 4 to 10, the population for use of any one of claims 2 and 4 to 10, or the PD-1 axis binding antagonist for use of any one of claims 3 to 10, wherein the CD8 co-receptor comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 and 4 to 11, the population for use of any one of claims 2 and 4 to 11, or the PD-1 axis binding antagonist for use of any one of claims 3 to 11, wherein the modified T cells are autologous with respect to the individual.

### Claim 13 (depends on 12)

The method, population for use, or PD-1 axis binding antagonist for use of claim 12, wherein the method comprises producing the population by:
(i) obtaining peripheral blood mononuclear cells (PBMCs) from the individual;
(ii) selecting T cells from the PBMCs; and
(iii) modifying the selected T cells to express a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 and 4 to 13, the population for use of any one of claims 2 and 4 to 13, or the PD-1 axis binding antagonist for use of any one of claims 3 to 13, wherein the method comprises administering lymphodepleting chemotherapy to the individual prior to administration of the population of modified T cells.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 and 4 to 14, the population for use of any one of claims 2 and 4 to 14, or the PD-1 axis binding antagonist for use of any one of claims 3 to 14, wherein the population comprises 0.8×109 to 10×109 modified T cells, optionally wherein the population comprises 0.8×109 to 1.2×109 modified T cells, 1.2×109 to 6×109 modified T cells, or 1.0×109 to 10×109 modified T cells.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 and 4 to 15, the population for use of any one of claims 2 and 4 to 15, or the PD-1 axis binding antagonist for use of any one of claims 3 to 15, wherein the population comprises about 1.0×109 modified T cells, about 5.0×109 modified T cells, or about 10×109 modified T cells.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 and 4 to 16, the population for use of any one of claims 2 and 4 to 16, or the PD-1 axis binding antagonist for use of any one of claims 3 to 16, wherein the population of modified T cells is administered as a single dose.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 and 4 to 17, the population for use of any one of claims 2 and 4 to 17, or the PD-1 axis binding antagonist for use of any one of claims 3 to 17, wherein the population of modified T cells is administered intravenously.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 and 4 to 18, the population for use of any one of claims 2 and 4 to 18, or the PD-1 axis binding antagonist for use of any one of claims 3 to 18, wherein the PD-1 axis binding antagonist is a PD1 binding antagonist.

### Claim 20 (depends on 19)

The method, population for use, or PD-1 axis binding antagonist for use of claim 19, wherein the PD1 binding antagonist is an antibody that binds PD-1.

### Claim 21 (depends on 20)

The method, population for use, or PD-1 axis binding antagonist for use of claim 20, wherein the antibody is nivolumab.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1 and 4 to 21, the population for use of any one of claims 2 and 4 to 21, or the PD-1 axis binding antagonist for use of any one of claims 3 to 21, wherein each dose of the PD-1 axis binding antagonist comprises 200 mg to 700 mg of the PD-1 axis binding antagonist.

### Claim 23 (depends on 22)

The method, population for use, or PD-1 axis binding antagonist for use of claim 22, wherein each dose of the PD-1 axis binding antagonist comprises 300 mg to 600 mg, 400 mg to 500 mg, 450 mg to 500 mg, or 480 mg of the PD-1 axis binding antagonist.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1 and 4 to 23, the population for use of any one of claims 2 and 4 to 23, or the PD-1 axis binding antagonist for use of any one of claims 3 to 23, wherein each dose of the PD-1 axis binding antagonist comprises 480 mg of nivolumab.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 and 4 to 24, the population for use of any one of claims 2 and 4 to 24, or the PD-1 axis binding antagonist for use of any one of claims 3 to 24, wherein the cancer expresses MAGE-A4 and/or is a solid tumour, optionally wherein the solid tumour is urothelial cancer, head and neck cancer, non-small cell lung cancer (NSCLC), oesophageal caner, oesophogastric cancer, gastric cancer, ovarian cancer, melanoma, or endometrial cancer.
